MRNA
Price
$195.00Alerts
Change
-$4.33 (-2.17%)
Updated
Nov 20 closing price
Capitalization
101.48B
96 days until earnings call
Intraday BUY SELL Signals
MRVI
Price
$6.98Alerts
Change
-$0.21 (-2.92%)
Updated
Nov 20 closing price
Capitalization
1.12B
95 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MRNA vs MRVI

MRNA vs MRVI Comparison Chart in %
View a ticker or compare two or three
A.I.Advisor
Nov 02, 2026

Which Stock Would AI Choose? Moderna (MRNA) vs. Maravai LifeSciences (MRVI) Stock Comparison

Key Takeaways

  • MRNA has delivered one of the standout rallies in the biotech sector in 2026, driven by late-stage personalized cancer vaccine data, a landmark flu vaccine approval, and inclusion in the Nasdaq-100 index.
  • MRVI is an early-stage turnaround story in the life sciences tools space, with narrowing losses, improving margins, and raised profitability guidance, though it still reports net losses on a GAAP basis.
  • The two companies occupy different positions in the value chain: Moderna is a therapeutic developer, while Maravai supplies the mRNA and bioprocess-testing inputs used across the broader biopharma industry.
  • Tickeron AI Verdict: Based on trend consistency, catalyst strength, and relative positioning, the AI currently favors MRNA over MRVI.
  • For more detail, explore MRNA Major News, MRNA Today's Price Move, MRVI Major News, and MRVI Today's Price Move.
  • To see which automated strategies are best suited to current market conditions, explore Trending AI Robots.

Introduction

This stock comparison examines two companies whose fortunes are linked to the same scientific platform—messenger RNA (mRNA)—yet which play very different roles in that ecosystem. MRNA (Moderna) is a therapeutic and vaccine developer whose shares have experienced dramatic relative performance in recent months. MRVI (Maravai LifeSciences) supplies the raw materials and testing services that mRNA developers rely on. Growth-oriented investors tracking high-momentum biotech, as well as those evaluating a turnaround with asymmetric risk, may find this comparison useful for understanding how market positioning, catalysts, and risk profiles diverge between the two names.

MRNA Overview and Recent Performance

Moderna develops medicines and vaccines based on messenger RNA (mRNA), the genetic instructions that cells use to make proteins. Following years of post-pandemic revenue contraction, recent market activity has reflected a sharp shift in sentiment. In 2026, the stock has risen substantially, with much of the move tied to positive late-stage results for intismeran autogene, a personalized mRNA-based cancer therapy developed with Merck, alongside the first U.S. Food and Drug Administration (FDA) approval of an mRNA-based seasonal flu vaccine. Broader catalysts—including early-stage hantavirus research, a next-generation COVID shot gaining market share, and addition to the Nasdaq-100 index—have reinforced the rally.

Despite the momentum, the fundamentals remain stretched by conventional measures. Moderna continues to report net losses, with trailing-twelve-month sales lower than a year earlier and an operating loss exceeding revenue. Recent weeks have also brought elevated volatility, including sharp single-day pullbacks as investors reassessed trial expectations and valuation. This combination of powerful catalysts and thin near-term profitability defines the current risk profile of MRNA.

MRVI Overview and Recent Performance

Maravai LifeSciences operates as a supplier to the biopharmaceutical industry rather than a drug developer. Its two main segments are TriLink BioTechnologies, which produces mRNA-related reagents including the CleanCap capping technology, and Cygnus Technologies, which provides bioprocess impurity testing such as host cell protein (HCP) assays. This positions the company as a leveraged play on mRNA research and manufacturing activity across the industry.

Recent quarters have shown a gradual improvement in operating performance. Revenue has grown year over year, gross margins have expanded, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) has swung positive, prompting management to raise its full-year profitability outlook. The company has also refinanced its debt to extend maturities. However, the turnaround remains incomplete: MRVI still posts net losses on a GAAP (Generally Accepted Accounting Principles) basis, revenue can be lumpy due to large, infrequent orders, and a recent quarterly report included a substantial goodwill impairment and a lowered revenue outlook, illustrating the uneven nature of the recovery.

Trending AI Robots

Tickeron's Trending AI Robots page curates a selection of the platform's AI trading bots, drawn from a broader library of hundreds of automated strategies that trade thousands of different tickers. Because market conditions change, only a subset of these bots—those judged most suitable for the current environment—earns a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance statistics, and set of tickers it trades, offering a range of approaches for different objectives. For traders seeking a systematic, data-driven way to evaluate setups like the MRNA and MRVI comparison, exploring Trending AI Robots can provide additional quantitative context.

Head-to-Head Comparison

The most fundamental contrast between these two stocks is their business model. Moderna bears development and regulatory risk in pursuit of blockbuster-scale products, while Maravai earns revenue by selling tools and services into the same industry, trading scale for a broader customer base. On growth drivers, Moderna's story centers on a few high-impact catalysts—cancer vaccines, respiratory vaccines, and geographic expansion—whereas Maravai's outlook depends on a wider recovery in biopharma research spending and steady conversion of discovery-stage customers into clinical-grade orders.

Recent momentum differs sharply. MRNA has posted exceptional returns but with elevated volatility and a valuation tied to products not yet selling in volume. MRVI has advanced more modestly, supported by margin improvement and balance-sheet repair, but remains constrained by persistent net losses, order lumpiness, and meaningful short interest. In terms of sector exposure, both carry biotech sensitivity, yet Moderna is a concentrated, high-beta (a measure of volatility relative to the broader market) growth name, while Maravai functions more as a diversified, cyclical supplier to the industry's research pipeline.

Tickeron AI Verdict

Weighing observable factors—trend consistency, catalyst strength, and relative positioning—Tickeron's AI currently leans toward MRNA over MRVI. Moderna's sustained uptrend, multiple clinical and regulatory catalysts, and expanding market recognition provide a more clearly defined momentum profile, even as its valuation and volatility warrant caution. Maravai's improving fundamentals are credible but remain uneven and partly dependent on factors outside its control, such as customer order timing. Accordingly, the AI would likely favor MRNA on a relative basis, while acknowledging that both names carry meaningful risk in the current environment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

VS
MRNA vs. MRVI commentary
Nov 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRNA is a Hold and MRVI is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for MRNA with price predictions
Nov 20, 2026

MRNA's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Oscillator for MRNA moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 26 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRNA as a result. In 74 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 33 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

MRNA moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

MRNA broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +11.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in 217 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

The Aroon Indicator entered an Uptrend today. In 108 of 130 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.010) is normal, around the industry mean (3.596). P/E Ratio (-31.853) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for MRVI with price predictions
Nov 20, 2026

MRVI in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 27, 2026

MRVI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 32 similar instances where the stock broke above the upper band. In 30 of the 32 cases the stock fell afterwards. This puts the odds of success at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRVI as a result. In 79 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for MRVI turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 39 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

MRVI moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The 10-day moving average for MRVI crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.

Following a +14.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRVI advanced for three days, in 204 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.475) is normal, around the industry mean (3.596). P/E Ratio (-14.189) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (4.785) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. MRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRVI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
MRNA vs MRVI: Fundamental Ratings
MRNA
MRVI
OUTLOOK RATING
1..100
6169
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
15
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
3437
P/E GROWTH RATING
1..100
9958
SEASONALITY SCORE
1..100
907

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRNA's Valuation (10) in the Biotechnology industry is in the same range as MRVI (15) in the null industry. This means that MRNA’s stock grew similarly to MRVI’s over the last 12 months.

MRNA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MRVI (100) in the null industry. This means that MRNA’s stock grew similarly to MRVI’s over the last 12 months.

MRNA's SMR Rating (97) in the Biotechnology industry is in the same range as MRVI (97) in the null industry. This means that MRNA’s stock grew similarly to MRVI’s over the last 12 months.

MRNA's Price Growth Rating (34) in the Biotechnology industry is in the same range as MRVI (37) in the null industry. This means that MRNA’s stock grew similarly to MRVI’s over the last 12 months.

MRVI's P/E Growth Rating (58) in the null industry is somewhat better than the same rating for MRNA (99) in the Biotechnology industry. This means that MRVI’s stock grew somewhat faster than MRNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MRNAMRVI
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 13 days ago
78%
Bullish Trend 13 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 1 day ago
83%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
83%
N/A
COMPARISON
Comparison
Nov 21, 2026
Stock price -- (MRNA: $195.00 vs. MRVI: $6.98)
Brand notoriety: MRNA: Notable vs. MRVI: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MRNA: 63% vs. MRVI: 76%
Market capitalization -- MRNA: $101.48B vs. MRVI: $1.12B
MRNA [@Biotechnology] is valued at $101.48B. MRVI’s [@Biotechnology] market capitalization is $1.12B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MRNA’s FA Score shows that 1 FA rating(s) are green while MRVI’s FA Score has 1 green FA rating(s).

  • MRNA’s FA Score: 1 green, 4 red.
  • MRVI’s FA Score: 1 green, 4 red.
According to our system of comparison, MRVI is a better buy in the long-term than MRNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MRNA’s TA Score shows that 3 TA indicator(s) are bullish while MRVI’s TA Score has 3 bullish TA indicator(s).

  • MRNA’s TA Score: 3 bullish, 6 bearish.
  • MRVI’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, MRVI is a better buy in the short-term than MRNA.

Price Growth

MRNA (@Biotechnology) experienced а -12.70% price change this week, while MRVI (@Biotechnology) price change was -7.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.

Reported Earning Dates

MRNA is expected to report earnings on Feb 25, 2027.

MRVI is expected to report earnings on Feb 24, 2027.

Industries' Descriptions

@Biotechnology (-11.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

MRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRVI has been loosely correlated with TWST. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MRVI jumps, then TWST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRVI
1D Price
Change %
MRVI100%
-2.92%
TWST - MRVI
50%
Loosely correlated
-7.44%
MRNA - MRVI
47%
Loosely correlated
-2.17%
RXRX - MRVI
46%
Loosely correlated
-9.93%
ARCT - MRVI
43%
Loosely correlated
-1.97%
BNTX - MRVI
43%
Loosely correlated
-0.52%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
QSR72.910.67
+0.93%
Restaurant Brands International
STVN15.65-0.28
-1.76%
Stevanato Group SpA
EML30.37-0.81
-2.60%
Eastern Company
AGBK5.09-0.25
-4.68%
AGI Inc
SINT1.10-0.08
-6.78%
SiNtx Technologies Inc.